What is BCG? How was it discovered? How did it become a common form of treatment for non-muscle invasive bladder cancer?
In this educational webinar, Dr. Alvaro Morales shares the fascinating history of BCG, from its origins as a tuberculosis vaccine to its groundbreaking use in bladder cancer treatment. Learn how his research established BCG as a cornerstone in bladder cancer treatments, saving countless bladders and lives over the past 50 years.
Facilitated by Dr. Madhuri Koti
Understanding BCG and Its Origins
BCG (Bacillus Calmette-Guérin) was initially developed over 100 years ago as a vaccine for tuberculosis. In the 1960s, researchers in Europe and North America began exploring its potential in cancer treatment, focusing on its immune-stimulating properties. Dr. Morales recognized bladder cancer as an ideal candidate due to its localized tumor nature, allowing direct application of live BCG into the bladder.
Dr. Morales’ Pioneering Work in Bladder Cancer
Dr. Morales administered the first BCG treatments for non-muscle invasive bladder cancer nearly 50 years ago at Queen’s University. His research established key parameters for successful BCG therapy:
- A small tumor load
- Direct contact of BCG with the tumor
- A sufficient number of live bacteria
- Patients with intact immune systems
These findings led to BCG becoming the first clinically proven immunotherapy for cancer and remain foundational in bladder cancer treatments today.
Impact and Validation of BCG Therapy
Subsequent large-scale trials in the United States confirmed Dr. Morales’ early findings, establishing BCG as the gold standard for non-muscle invasive bladder cancer. Clinical research demonstrated a significant reduction in tumor recurrence while maintaining safety for patients.
Ongoing Developments and Emerging Therapies
While BCG has been remarkably effective, 30–40% of patients do not respond to this treatment. Researchers are exploring emerging bladder cancer therapies to improve outcomes, including:
- Immune checkpoint inhibitors
- Oncolytic viruses and adenoviral vectors
- Recombinant BCG strains such as VPM1002 and MTB VAC
- Genetically modified BCG
These advancements aim to complement BCG, offering safer and more effective options for both BCG-naive and BCG non-responsive patients.
BCG Production and Strains
BCG is a live bacterium, and its production is more complex than chemical drugs like ibuprofen. Different strains exist worldwide, derived from the original French BCG culture. Strain differences can affect immune response, efficacy, and side effects, and ongoing trials are examining optimal strains for bladder cancer treatment.
Staying Informed and Supported with Bladder Cancer Canada
Bladder Cancer Canada provides resources, webinars, and patient support to help individuals navigate BCG treatment and other bladder cancer therapies. Staying informed empowers patients and caregivers to make the best decisions about their care.
